Low ADAMTS-13 activity during hemorrhagic events with disseminated intravascular coagulation (Q43839468)

27 November 2017

title

Low ADAMTS-13 activity during hemorrhagic events with disseminated intravascular coagulation (English)

1 reference

27 November 2017

Masafumi Taniwaki

1 reference

27 November 2017

Yoshiaki Chinen

1 reference

27 November 2017

Junya Kuroda

1 reference

27 November 2017

Muneo Ohshiro

1 reference

27 November 2017

Yuji Shimura

1 reference

27 November 2017

Shinsuke Mizutani

1 reference

27 November 2017

Hisao Nagoshi

1 reference

27 November 2017

Nana Sasaki

1 reference

27 November 2017

Ryuko Nakayama

1 reference

27 November 2017

Miki Kiyota

1 reference

27 November 2017

Mio Yamamoto-Sugitani

1 reference

27 November 2017

Tsutomu Kobayashi

1 reference

27 November 2017

Yosuke Matsumoto

1 reference

27 November 2017

Shigeo Horiike

1 reference

27 November 2017

publication date

14 March 2013

1 reference

International Journal of Hematology

27 November 2017

published in

1 reference

27 November 2017

1 reference

27 November 2017

1 reference

27 November 2017

page(s)

511-519

1 reference

Disseminated intravascular coagulation: old disease, new hope

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

The interactions between inflammation and coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Disseminated intravascular coagulation in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Disseminated intravascular coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Efficacy and safety of recombinant human activated protein C for severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Thrombomodulin alfa in the treatment of infectious patients complicated by disseminated intravascular coagulation: subanalysis from the phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Partial amino acid sequence of purified von Willebrand factor-cleaving protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Thrombotic Microangiopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Thrombotic thrombocytopenic purpura: recognition and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Correlation between plasma activity of ADAMTS-13 and coagulopathy, and prognosis in disseminated intravascular coagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Proteolytic inactivation of ADAMTS13 by thrombin and plasmin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

ADAMTS13: a new link between thrombosis and inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel antiinflammatory mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Prophylactic fresh frozen plasma may prevent development of hepatic VOD after stem cell transplantation via ADAMTS13-mediated restoration of von Willebrand factor plasma levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Localization of ADAMTS13 to the stellate cells of human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1308-X

Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)

21 January 2018

1 reference

12 December 2020

Unfractioned heparin for treatment of sepsis: A randomized clinical trial (The HETRASE Study)

1 reference

12 December 2020

Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.

1 reference

12 December 2020

ADAMTS-13 activity can predict the outcome of disseminated intravascular coagulation in hematologic malignancies treated with recombinant human soluble thrombomodulin

1 reference

12 December 2020

Proteolytic fragmentation and sugar chains of plasma ADAMTS13 purified by a conformation-dependent monoclonal antibody

1 reference

12 December 2020

Disseminated intravascular coagulation

1 reference

12 December 2020

Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial

1 reference

12 December 2020

Disseminated intravascular coagulation in sepsis

1 reference

12 December 2020

Fatal intracranial hemorrhage following administration of recombinant thrombomodulin in a patient after cord blood transplantation

1 reference

12 December 2020

Recombinant human soluble thrombomodulin for treatment of thrombotic microangiopathy associated with lupus nephritis

1 reference

12 December 2020

Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation

1 reference

12 December 2020

10.1007/S12185-013-1308-X

Identifiers

DOI

1 reference

27 November 2017

1 reference